NEDD9 is a Positive Regulator of Epithelial-mesenchymal Transition and Promotes Invasion in Aggressive Breast Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Aug 11

PMID 21829474

Citations 55

Authors

Chenfei Kong

Changqing Wang

Liping Wang

Musong Ma

Chunbo Niu

Xiaoqian Sun

Juan Du

Zhixiong Dong

Shan Zhu

Jun Lu

Baiqu Huang

Affiliations

Soon will be listed here.

Abstract

Epithelial to mesenchymal transition (EMT) plays an important role in many biological processes. The latest studies revealed that aggressive breast cancer, especially the triple-negative breast cancer (TNBC) subtype was frequently associated with apparent EMT, but the mechanisms are still unclear. NEDD9/HEF1/Cas-L is a member of the Cas protein family and was identified as a metastasis marker in multiple cancer types. In this study, we wished to discern the role of NEDD9 in breast cancer progression and to investigate the molecular mechanism by which NEDD9 regulates EMT and promotes invasion in triple-negative breast cancer. We showed that expression of NEDD9 was frequently upregulated in TNBC cell lines, and in aggressive breast tumors, especially in TNBC subtype. Knockdown of endogenous NEDD9 reduced the migration, invasion and proliferation of TNBC cells. Moreover, ectopic overexpression of NEDD9 in mammary epithelial cells led to a string of events including the trigger of EMT, activation of ERK signaling, increase of several EMT-inducing transcription factors and promotion of their interactions with the E-cadherin promoter. Data presented in this report contribute to the understanding of the mechanisms by which NEDD9 promotes EMT, and provide useful clues to the evaluation of the potential of NEDD9 as a responsive molecular target for TNBC chemotherapy.

Citing Articles

The Prognostic Significance of NEDD9 Expression in Human Cancers: A Systematic Review, Meta-Analysis, and Omics Exploration.

Yasin J, Odat R, Qtaishat F, Tamimi M, Alsufi M, Younis O Technol Cancer Res Treat. 2024; 23:15330338241297597.

PMID: 39540210 PMC: 11561999. DOI: 10.1177/15330338241297597.

Increased glycolysis and cellular crosstalk in eosinophilic chronic rhinosinusitis with nasal polyps.

Huang G, Mandanas M, Djeddi S, Fernandez-Salinas D, Gutierrez-Arcelus M, Barrett N Front Immunol. 2024; 15:1321560.

PMID: 38444858 PMC: 10912276. DOI: 10.3389/fimmu.2024.1321560.

Isorhapontigenin (ISO) inhibits malignant cell transformation, migration, and invasion through MEG3/NEDD9 signaling in Cr(VI)-transformed cells.

Shi S, Li J, Zhang Z, Tu H, Max C Toxicol Appl Pharmacol. 2023; 476:116661.

PMID: 37619952 PMC: 10874125. DOI: 10.1016/j.taap.2023.116661.

Unravelling the Therapeutic Potential of Antibiotics in Hypoxia in a Breast Cancer MCF-7 Cell Line Model.

Akhunzianov A, Nesterova A, Wanrooij S, Filina Y, Rizvanov A, Miftakhova R Int J Mol Sci. 2023; 24(14).

PMID: 37511298 PMC: 10380719. DOI: 10.3390/ijms241411540.

ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization.

Lyon A, Tripathi R, Meeks C, He D, Wu Y, Liu J Cancers (Basel). 2023; 15(3).

PMID: 36765910 PMC: 9913232. DOI: 10.3390/cancers15030954.

References

Natarajan M, Stewart J, Golemis E, Pugacheva E, Alexandropoulos K, Cox B . HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene. 2005; 25(12):1721-32. DOI: 10.1038/sj.onc.1209199. View

Wang X, Pan L, Feng Y, Wang Y, Han Q, Han L . P300 plays a role in p16(INK4a) expression and cell cycle arrest. Oncogene. 2007; 27(13):1894-904. DOI: 10.1038/sj.onc.1210821. View

von Burstin J, Eser S, Paul M, Seidler B, Brandl M, Messer M . E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009; 137(1):361-71, 371.e1-5. DOI: 10.1053/j.gastro.2009.04.004. View

Thiery J, Chopin D . Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev. 1999; 18(1):31-42. DOI: 10.1023/a:1006256219004. View

Timmerman L, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares J, Diez J . Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004; 18(1):99-115. PMC: 314285. DOI: 10.1101/gad.276304. View

Storci G, Sansone P, Trere D, Tavolari S, Taffurelli M, Ceccarelli C . The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol. 2007; 214(1):25-37. DOI: 10.1002/path.2254. View

Jorda M, Olmeda D, Vinyals A, Valero E, Cubillo E, Llorens A . Upregulation of MMP-9 in MDCK epithelial cell line in response to expression of the Snail transcription factor. J Cell Sci. 2005; 118(Pt 15):3371-85. DOI: 10.1242/jcs.02465. View

Giampieri S, Manning C, Hooper S, Jones L, Hill C, Sahai E . Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009; 11(11):1287-96. PMC: 2773241. DOI: 10.1038/ncb1973. View

Finn R, Dering J, Ginther C, Wilson C, Glaspy P, Tchekmedyian N . Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007; 105(3):319-26. DOI: 10.1007/s10549-006-9463-x. View

10.

Moyano J, Evans J, Chen F, Lu M, Werner M, Yehiely F . AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest. 2006; 116(1):261-70. PMC: 1323258. DOI: 10.1172/JCI25888. View

11.

Xia D, Holla V, Wang D, Menter D, DuBois R . HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Res. 2010; 70(2):824-31. PMC: 2943830. DOI: 10.1158/0008-5472.CAN-09-2105. View

12.

Gupta G, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K . ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A. 2007; 104(49):19506-11. PMC: 2148319. DOI: 10.1073/pnas.0709185104. View

13.

Mani S, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N . Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A. 2007; 104(24):10069-74. PMC: 1891217. DOI: 10.1073/pnas.0703900104. View

14.

Peinado H, Ballestar E, Esteller M, Cano A . Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol. 2003; 24(1):306-19. PMC: 303344. DOI: 10.1128/MCB.24.1.306-319.2004. View

15.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

16.

Shin S, Dimitri C, Yoon S, Dowdle W, Blenis J . ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell. 2010; 38(1):114-27. PMC: 2854677. DOI: 10.1016/j.molcel.2010.02.020. View

17.

Livasy C, Karaca G, Nanda R, Tretiakova M, Olopade O, Moore D . Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2005; 19(2):264-71. DOI: 10.1038/modpathol.3800528. View

18.

Ji H, Ramsey M, Hayes D, Fan C, McNamara K, Kozlowski P . LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007; 448(7155):807-10. DOI: 10.1038/nature06030. View

19.

Bauer K, Brown M, Cress R, Parise C, Caggiano V . Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109(9):1721-8. DOI: 10.1002/cncr.22618. View

20.

Fidler I . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-8. DOI: 10.1038/nrc1098. View